Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease.

@article{Mandorfer2016InterferonfreeTW,
  title={Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease.},
  author={Mattias Mandorfer and Philipp Schwabl and Sebastian Steiner and Bernhard Scheiner and David Chromy and Theresa Bucsics and Albert Friedrich Staettermayer and Maximilian Christopher Aichelburg and Katharina Grabmeier-Pfistershammer and Michael Trauner and Thomas Reiberger and Markus Peck-Radosavljevic},
  journal={AIDS},
  year={2016},
  volume={30 7},
  pages={1039-47}
}
AIM We aimed to investigate the safety and efficacy of interferon (IFN) and ribavirin (RBV)-free therapy with sofosbuvir along with daclatasvir (SOF/DCV) in HIV/hepatitis C virus (HCV)-coinfected patients (HIV/HCV), who have an urgent need for effective antiviral therapy. We also assessed its impact on liver stiffness and liver enzymes. DESIGN Thirty-one patients thoroughly documented HIV/HCV with advanced liver disease (advanced liver fibrosis and/or portal hypertension) who were treated… CONTINUE READING
5 Extracted Citations
41 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 41 references

Similar Papers

Loading similar papers…